You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension
SBC: INOVODEL, INC. Topic: NHLBISUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises and Experts
SBC: Insitehub LLC Topic: NIGMSSummary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention
SBC: FORTISCIENCE, INC. Topic: NHLBIProject Summary Project Title: Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention. Atherosclerosis affects more than 18 million Americans and is a major cause of cardiovascular diseases and acute cardiovascular events, such as heart attack and stroke. Current interventions include changes to diet and exercise, smoking cessation, and treatment with st ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
High-throughput functional analysis and clinical relevance of all possible variants of a gene
SBC: HELIGENICS, INC. Topic: NHGRIModern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
SBC: EPIVAX, INC. Topic: NIAIDABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel TLR-4 Agonists as Vaccine Adjuvants
SBC: HAWAII BIOTECH, INC. Topic: NIAIDAbstract/Project SummaryAlong with the many benefits of a global economy hides the ever-present risk for the world wide spread of infectious disease. While significant outbreaks of the flu in the recent past involving millions of individuals could be contained, the emergence and rapid spread of the SARS-CoV-2 virus revealed how vulnerable and unprepared the world population was to combat a previou ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care lateral flow immunoassay for diagnosis of pertussis
SBC: DXDISCOVERY INC Topic: NIAIDPertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of multimode vacuum ionization for use in medical diagnostics
SBC: MSTM LLC Topic: NIAIDThere is a critical need for rapid and cost-effective means for the detection of e.g. infectious diseases at an early stage, drug overdoses, and other health related testing necessities. Thus, significant commercial opportunities exist because of the lack of these capabilities as painfully “demonstrated” in the current pandemic. Mass spectrometry (MS), because of its ability to detect hundreds ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
SBC: HAWAII BIOTECH, INC. Topic: NIAID7. Project Summary/Abstract The encephalitic New World alphaviruses (NWAVs), consisting of Eastern, Venezuelan and Western Equine Encephalitis Viruses (EEEV, VEEV and WEEV, respectively), are transmitted by mosquitoes through rodent or bird hosts and have caused significant periodic epizootic outbreaks in equines and humans in the Americas. NWAVs can cause severe neurological disease, with fatal e ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health